Company Overview of H3 Biomedicine Inc.
H3 Biomedicine Inc., a biopharmaceutical company, is engaged in the discovery and development of small-molecule drugs to treat cancer. H3 Biomedicine Inc. has a strategic collaboration with Selvita S.A. The company was founded in 2010 and is based in Cambridge, Massachusetts. H3 Biomedicine Inc. operates as a subsidiary of Eisai Inc.
300 Technology Square
Cambridge, MA 02139
Founded in 2010
Key Executives for H3 Biomedicine Inc.
President and Chief Executive Officer
Senior Vice President of Planning and Operations
Associate Director of Business Development
Compensation as of Fiscal Year 2015.
H3 Biomedicine Inc. Key Developments
H3 Biomedicine Inc. Presents at Boston Biotech BD Boston Conference, Mar-26-2014 04:00 PM
Mar 24 14
H3 Biomedicine Inc. Presents at Boston Biotech BD Boston Conference, Mar-26-2014 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Markus Warmuth, President and Chief Executive Officer.
H3 Biomedicine Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:50 PM
Sep 25 13
H3 Biomedicine Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 01:50 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Markus Warmuth, President and Chief Executive Officer.
H3 Biomedicine Inc and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Sep 16 13
H3 Biomedicine Inc. and Selvita announced that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries